Rocket Pharmaceuticals, Inc. - Special Call Transcript
Welcome to the ASH 2020 Investor and Analyst Conference Call. My name is Sylvia, and I'll be operator for today's call. (Operator Instructions) Please note that this conference is being recorded.
I will now turn the call over to Claudine Prowse. Claudine, you may begin.
Thank you, Sylvia. Good evening. I want to thank everyone for joining us for ASH 2020 Conference Call. We'll be focusing on our 3 lenti programs: Fanconi Anemia, Leukocyte Adhesion Deficiency-I and Pyruvate Kinase Deficiency. If you are not joining us live, the webcast will be available on our website at rocketpharma.com.
My name is Claudine Prowse, I am Senior Vice President of Strategy and Corporate Development, and several participants from the Rocket executive leadership team are joining me on this call, including Dr. Gaurav Shah, our Chief Executive Officer and President; Dr. Jonathan Schwartz, our Chief Medical Officer; Kinnari Patel, our Chief Operating
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |